Research led by Professor Hai-Ling Margaret Cheng (BME) opens the door to earlier treatment and better outcomes ...

Cytokinetics (CYTK) announced that AMBER-HFpEF is open to enrollment. AMBER-HFpEF is a Phase 2 randomized, placebo-controlled, double-blind, ...

The company shared interim results from an ongoing Phase II trial examining its recombinant antibody fusion protein.

Cytokinetics, Inc. (CYTK), a biopharmaceutical company focused on muscle biology, on Monday announced the launch of the AMBER-HFpEF ...

Shares of Cytokinetics CYTK gained 2.2% on Wednesday after the company began enrolling patients in its mid-stage study of CK-4021586 (CK-586), a cardiac myosin inhibitor, for treating heart failure ...

The role of ACE inhibitors in the management of HFPEF is less significant compared with their role in the management of heart failure with left ventricular systolic dysfunction. For patients with ...

Faun1083 has demonstrated positive in-vivo efficacy in multiple preclinical animal models, including rat sugen hypoxia and ...

The section presents a review of diastolic congestive heart failure, commonly called HFpEF. Reviews of systolic congestive HF, or HFrEF, valvular heart disease, pulmonary hypertension and right HF ...

The message is that an early decrease in eGFR with finerenone should not lead to stopping the medication, say HF experts.

The company is developing TX45 to treat group 2 pulmonary hypertension in patients with preserved ejection fraction heart failure or known as HFpEF. The goal for Tectonic for 2025 is beating AZ ...

GAITHERSBURG, MD, USA I2, 2025 I Salubris Biotherapeutics, Inc. (SalubrisBio), a clinical-stage biotechnology company dedicated to discovering and developing novel complex biologic therapeutics, today ...